

Table of contents

Contents

Scientific summary.....	i
Acknowledgements.....	ii
Résumé	iii
Résumé large public:.....	iv
List of abbreviations.....	v
Table of Contents.....	viii
1. Introduction	1
1.1. Leishmaniasis	1
1.2. Clinical Manifestation of leishmaniasis	1
1.3. Pathogenesis of leishmaniasis.....	3
1.4. Leishmaniasis in Ethiopia	6
1.4.1. Cutaneous leishmaniasis in Ethiopia	7
1.4.2. Visceral leishmaniasis.....	7
1.4.3. HIV co-infection of VL.....	9
1.5. Immune response to <i>Leishmania</i>	9
1.5.1. Innate response in experimental leishmaniasis	9
1.5.2. Adaptive immunity.....	19
1.6. Arginase	22
1.6.1. What is arginase?	22
1.6.1. Arginase and nitric oxide synthase.....	25
1.6.3. Expression and regulation of arginase	25
<i>In vitro</i> stimulation of human myeloid cells.....	26
1.6.4. Human disease	30
1.6.5. Phenotype of cells expressing arginase.....	31
1.6.6. Immunosuppressive mechanisms of arginase	32
2. Aims of this PhD study	34
Aim 1: LCL.....	34
Aim 2: VL.....	34
Aim 3: VL/HIV co-infection.....	34
3. Materials and methods	35
3.1. Chemicals, solutions and antibodies used in the project.....	35
3.2. Patient recruitment, inclusion and exclusion.....	37
3.2.1. Cohort 1 (Cutaneous leishmaniasis, n=15).....	37
3.2.2. Cohort 2 (Visceral leishmaniasis, n=26)	38

3.2.3.	Cohort 3 (VL/ HIV- co-infected, n= 14)	39
3.2.4.	Healthy controls	40
3.3.	Sample collection and processing	40
3.3.1.	Peripheral Blood	40
3.3.2.	Biopsy	41
3.4.	Arginase activity	42
3.5.	Protein determination	43
3.5.1.	Calculation of arginase activity (mU/mg protein)	43
3.6.	Flow cytometry	43
3.6.1.	Phenotype, frequency and extent of degranulation of arginase expressing cells in PBMC	43
3.6.2.	Phenotype of cells expressing arginase in skin biopsy	44
3.6.3.	Expression of CD3 ξ in CD4 ⁺ and CD8 ⁺ T cell in PBMC of VL patients	45
3.6.4.	Expression level of CD3 ξ , CD4 and CD8 molecules in biopsies and PBMC of CL patients	45
3.6.5.	CD4 ⁺ and CD8 ⁺ T cells count in blood of VL patients	45
3.7.	Plasma concentration of L-arginine	46
3.8.	HIV test	46
3.9.	Hematological data	46
3.10.	Ethical considerations	47
3.11.	Statistical analysis	47
4.	Results	48
4.1.	Local Increase of Arginase Activity in Lesions of Patients with Cutaneous Leishmaniasis in Ethiopia	48
4.1.1.	Aim of CL study	49
4.2.	Arginase: a Marker of Disease Status in Patients with Visceral Leishmaniasis.	61
4.2.1.	Aim of the VL study	62
4.3.	Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection... ..	73
4.3.1.	Aim of the VL/HIV co-infection study	74
5.	Discussion	83
5.1.	Arginase activity in CL	83
5.2.	Arginase activity in VL	83
5.3.	Impact of L-arginine depletion due to arginase activation in CL	84
5.4.	Impact of L-arginine depletion due to arginase activation in VL	85
5.5.	Arginase activity in HIV/VL coinfection	86
5.6.	Cells expressing arginase in leishmaniasis	87

6. Future directions.....	89
6.1. Cutaneous leishmaniasis	89
6.2. VL project	91
6.3. VL/HIV co-infections	93
7. Annexes.....	97
Annex 1: Local Increase of Arginase Activity in Lesions of Patients with Cutaneous Leishmaniasis in Ethiopia (pdf)	97
Annex 2: Arginase activity – A Marker of Disease Status in Patients with Visceral Leishmaniasis in Ethiopia (pdf)	97
Annex 3: Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection (pdf).....	97
Annex 4: A complete CV (pdf)	97
8. References	98